ACC 2023 Poster: First-In-Human Study of lorundrostat, a Potent and Highly Selective Aldosterone Synthase Inhibitor
ACC 2023 Poster: Highly Effective Blood Pressure Lowering with lorundrostat, a New Aldosterone Synthase Inhibitor, in Individuals with Obesity and RAAS Dysregulation
